1. Field of the Invention
This application is directed to pumps for mechanical circulatory support of a heart. In particular, this application is directed to a console and controller for a catheter pump and a fluid handling system configured to convey and remove fluids to and from the catheter pump.
2. Description of the Related Art
Heart disease is a major health problem that has high mortality rate. Physicians increasingly use mechanical circulatory support systems for treating heart failure. The treatment of acute heart failure requires a device that can provide support to the patient quickly. Physicians desire treatment options that can be deployed quickly and minimally-invasively.
Intra-aortic balloon pumps (IABP) are currently the most common type of circulatory support devices for treating acute heart failure. IABPs are commonly used to treat heart failure, such as to stabilize a patient after cardiogenic shock, during treatment of acute myocardial infarction (MI) or decompensated heart failure, or to support a patient during high risk percutaneous coronary intervention (PCI). Circulatory support systems may be used alone or with pharmacological treatment.
In a conventional approach, an IABP is positioned in the aorta and actuated in a counterpulsation fashion to provide partial support to the circulatory system. More recently, minimally-invasive rotary blood pumps have been developed in an attempt to increase the level of potential support (i.e., higher flow). A rotary blood pump is typically inserted into the body and connected to the cardiovascular system, for example, to the left ventricle and the ascending aorta to assist the pumping function of the heart. Other known applications pumping venous blood from the right ventricle to the pulmonary artery for support of the right side of the heart. An aim of acute circulatory support devices is to reduce the load on the heart muscle for a period of time, to stabilize the patient prior to heart transplant or for continuing support.
There is a need for improved mechanical circulatory support devices for treating acute heart failure. Fixed cross-section ventricular assist devices designed to provide near full heart flow rate are either too large to be advanced percutaneously (e.g., through the femoral artery without a cutdown) or provide insufficient flow.
There is a need for a pump with improved performance and clinical outcomes. There is a need for a pump that can provide elevated flow rates with reduced risk of hemolysis and thrombosis. There is a need for a pump that can be inserted minimally-invasively and provide sufficient flow rates for various indications while reducing the risk of major adverse events. In one aspect, there is a need for a heart pump that can be placed minimally-invasively, for example, through a 15 FR or 12 FR incision. In one aspect, there is a need for a heart pump that can provide an average flow rate of 4 Lpm or more during operation, for example, at 62 mmHg of head pressure. While the flow rate of a rotary pump can be increased by rotating the impeller faster, higher rotational speeds are known to increase the risk of hemolysis, which can lead to adverse outcomes and in some cases death. Accordingly, in one aspect, there is a need for a pump that can provide sufficient flow at significantly reduced rotational speeds. These and other problems are overcome by the inventions described herein.
Furthermore, in various catheter pump systems, it can be important to provide fluids to an operative device of a catheter assembly (e.g., for lubrication of moving parts and/or treatment fluids to be delivered to the patient), and to remove waste fluids from the patient's body. A controller may be provided to control the flow into and out of the catheter assembly. It can be advantageous to provide improved mechanisms for engaging the catheter assembly with the controller, which may be housed in a console.
Additionally, there is a need to reduce the time to implantation and treatment. In the case of therapy for acute heart failure in particular, the time it takes to start therapy can be critical to survival and good outcomes. For example, a difference of several minutes can be the difference between recovery and permanent brain damage for patients suffering myocardial infarction or cardiogenic shock. Accordingly, a continuing need exists to provide pump systems that can be set up, primed, and inserted faster, easier, and more effectively.
These and other problems are overcome by the inventions described herein.
There is an urgent need for a pumping device that can be inserted percutaneously and also provide full cardiac rate flows of the left, right, or both the left and right sides of the heart when called for.
In one embodiment, a fluid handling system is disclosed. The system can include a housing. The housing can include one or more pumps, and a controller configured to operate the pump(s). The system can further include a catheter assembly. The catheter assembly may include a catheter body having a proximal portion and an operative device at a distal portion. An infusion system can be in fluid communication with the proximal portion of the catheter body. The infusion system can include a closure member configured to be separate from the housing in a first state and to at least partially secure the infusion system to the housing in a second state. Upon engagement of the closure member with the housing in the second state, the infusion system may be operably engaged with the pump(s).
In another embodiment, a removable interface member for a fluid handling system is disclosed. The interface member can include an interface body sized and shaped to be inserted into an interface aperture of a console housing. An electrical component can be disposed on the interface body. Furthermore, an occlusion bed can be disposed on the interface body. A tube segment can be disposed on the interface body near the occlusion bed. The interface body can be dimensioned such that when the interface body is inserted into the interface aperture of the console housing, a pump in the console housing is operably engaged with the tube segment and the occlusion bed, and an electrical interconnect in the console housing is electrically coupled with the electrical component on the interface body.
In yet another embodiment, a method for operably coupling an infusion system to a console housing is disclosed. The method can comprise positioning an interface body of the infusion system in an interface aperture of the console housing. The interface body can comprise an occlusion bed, a tube segment mounted on the interface body near the occlusion bed, and an electrical component. The method can further comprise inserting the interface body through the interface aperture until a pump roller of the console housing compresses the tube segment against the occlusion bed and until an electrical interconnect of the console housing is electrically coupled to the electrical component of the interface body.
In another embodiment, a method for priming a catheter assembly is disclosed. The catheter assembly can include an elongate body and an operative device. The method can comprise inserting the operative device of the catheter assembly into a priming vessel. The method can further comprise securing a proximal portion of the priming vessel to a distal portion of the elongate body, such that the elongate body is in fluid communication with the priming vessel. Fluid can be delivered through the elongate body and the priming vessel to expel air within the catheter assembly.
A more complete appreciation of the subject matter of this application and the various advantages thereof can be realized by reference to the following detailed description, in which reference is made to the accompanying drawings in which:
More detailed descriptions of various embodiments of components for heart pumps useful to treat patients experiencing cardiac stress, including acute heart failure, are set forth below.
This application is directed to fluid handling systems that are configured to control and/or manage fluid and electrical pathways in a catheter assembly, such as a catheter assembly of a percutaneous heart pump system. In particular, the disclosed percutaneous heart pump systems may include a catheter assembly and a console that includes a controller configured to control the fluid and electrical pathways that pass through the catheter assembly. Some of the disclosed embodiments generally relate to various configurations for coupling and engaging the catheter assembly with the console. For example, the console may be configured to control the flow rate of the pump and to monitor various physiological parameters and pump performance through the various electrical and fluid pathways of the catheter assembly. In some arrangements, the catheter assembly may be disposable, such that the catheter assembly can be discarded after use, while the console and controller are reusable. In embodiments with a reusable console and a disposable catheter assembly (or, indeed, in any embodiments where consoles and catheter assemblies may be coupled), it can be desirable to provide an effective interface between the catheter assembly and the console that completes the various fluid and electrical connections between the catheter assembly and the console.
In particular, it can be advantageous to provide an interface member at a proximal portion of the catheter assembly that is removably engageable with the console. Furthermore, to enhance usability and to minimize mistakes in making the connections, it can be important to make the interface easy to use so that users can easily connect the catheter assembly to the console before use and easily remove the catheter assembly from the console after use. Moreover, it can be important that the interface provides a secure connection between the interface member of the catheter assembly and an interface region of the console to ensure that the catheter assembly remains connected to the console uninterrupted during treatment.
As explained herein, one example of a catheter assembly is used in a percutaneous heart pump system having an operative device (e.g., an impeller assembly) that is configured to assist the patient's heart in pumping blood. The heart pump system may be configured to at least temporarily support the workload of the left ventricle in some embodiments. The exemplary heart pump can be designed for percutaneous entry through the femoral artery to a patient's heart. In particular, the exemplary impeller assembly can include a collapsible impeller and cannula, which can be inserted into the patient's vasculature at a catheter size of less than 13 FR, for example, about 12.5 FR in some arrangements. During insertion through the patient's vascular system to the heart, a sheath may maintain the impeller and cannula assembly in a stored configuration. When the impeller assembly is positioned in the left ventricle (or another chamber of a patient's heart), the impeller and cannula can expand to a larger diameter, for example to a catheter size of about 24 FR when the sheath is removed from the impeller assembly. The expanded diameter of the impeller and cannula may allow for the generation of higher flow rates, according to some embodiments.
For example,
Turning to
Moving from the distal end of the catheter assembly 100A of
With continued reference to
As explained above, the catheter body 120A can couple to the driven assembly 101 of the motor assembly. The driven assembly 101 can be configured to receive torque applied by the drive assembly 103, which is shown as being decoupled from the driven assembly 101 and the catheter assembly 100A in
Although not shown in
As shown in
The mechanical components rotatably supporting the impeller within the impeller assembly 116A permit high rotational speeds while controlling heat and particle generation that can come with high speeds. The infusion system 195 may deliver a cooling and lubricating solution to the distal portion of the catheter assembly 100A for these purposes. As shown in
When activated, the catheter pump system can effectively increase the flow of blood out of the heart and through the patient's vascular system. In various embodiments disclosed herein, the pump can be configured to produce a maximum flow rate (e.g. low mm Hg) of greater than 4 Lpm, greater than 4.5 Lpm, greater than 5 Lpm, greater than 5.5 Lpm, greater than 6 Lpm, greater than 6.5 Lpm, greater than 7 Lpm, greater than 7.5 Lpm, greater than 8 Lpm, greater than 9 Lpm, or greater than 10 Lpm. In various embodiments, the pump can be configured to produce an average flow rate at 62 mmHg pressure head of greater than 2 Lpm, greater than 2.5 Lpm, greater than 3 Lpm, greater than 3.5 Lpm, greater than 4 Lpm, greater than 4.25 Lpm, greater than 4.5 Lpm, greater than 5 Lpm, greater than 5.5 Lpm, or greater than 6 Lpm.
Various aspects of the pump and associated components are similar to those disclosed in U.S. Pat. Nos. 7,393,181; 8,376,707; 7,841,976; 7,022,100; and 7,998,054, and in U.S. Pub. Nos. 2011/0004046; 2012/0178986; 2012/0172655; 2012/0178985; and 2012/0004495, the entire contents of each of which are incorporated herein for all purposes by reference. In addition, this application incorporates by reference in its entirety and for all purposes the subject matter disclosed in each of the following concurrently filed applications: application Ser. No. 13/802,556, entitled “DISTAL BEARING SUPPORT,” filed on Mar. 13, 2013; application Ser. No. 13/801,833, entitled “SHEATH SYSTEM FOR CATHETER PUMP,” filed on Mar. 13, 2013; application Ser. No. 13/802,570, “IMPELLER FOR CATHETER PUMP,” filed on Mar. 13, 2013; application Ser. No. 13/801,528, entitled “CATHETER PUMP,” filed on Mar. 13, 2013; and application Ser. No. 13/802468, entitled “MOTOR ASSEMBLY FOR CATHETER PUMP,” filed on Mar. 13, 2013.
Fluid Handling System
In some embodiments, the fluid handling system 350 can be configured to deliver fluids to and/or remove fluids from the catheter assembly 100A. As discussed above and in the incorporated patent references, saline and/or other medical solutions can lubricate and/or cool component between the motor assembly and the operative device. If desired, waste fluids can be removed from the catheter assembly 100A using the fluid handling system 350. In some embodiments, the fluid handling system 350 can include a multilumen catheter body having a proximal end and a distal end. The catheter body can include one or more lumens through which medical solutions (e.g., saline), waste fluids, and/or blood can flow. To drive fluid through the catheter assembly 100A (e.g., into and/or out of the catheter assembly 100A), the console 301 may include one or more pump(s) configured to apply positive or negative pressure to the catheter assembly 100A when the catheter assembly 100A is coupled to the console 301 and engages the pump(s).
In addition, the fluid handling system 350 may also be configured to provide electrical communication between the console 301 and the catheter assembly 100A. For example, the console can include a controller (e.g., a processor) that is programmed to control and/or manage the operation of the motor assembly. The console 301 may also include electrical interfaces configured to supply power to the motor assembly and/or other components that are driven by electrical power when the interface member 300 is coupled to the console 301. Moreover, one or more electrical or electronic sensors may be provided in the catheter assembly 100A and may electrically couple to the console 301 by way of the fluid handling system 350. The embodiments disclosed herein may thereby provide fluid and electrical connections between the catheter assembly 100A and the console 301.
As explained above, the fluid handling system 350 may provide a removable interface between the catheter assembly 100A and the console 301, which may include various components, including, e.g., one or more pump(s), processors (e.g., the controller), electrical interconnections, etc. For example, to activate one or more pumps in the console 301 and/or to engage one or more electrical connections between the console 301 and the interface member 300, a user may simply insert a distal portion of the interface member 300 (e.g., including a closure member) along the illustrated Z-direction into an aperture 304 of the interface region 303 until the pump(s) are engaged and the electrical connection(s) are formed. In some aspects, the insertion of the interface member along the Z-direction may engage the pump(s) and complete the electrical connection(s) substantially simultaneously.
In some embodiments, the interface member 300 may be secured to the console 301 by engaging a locking device between the interface region 303 and the interface member 300. One convenient way to engage a locking device is by rotating a portion of the interface member 300 relative to another portion of the interface member or relative to the console 301, as explained herein. For example, rotation of an outermost structure (opposite the direction Z), sometimes referred to herein as a “cap” relative to the console may engage a locking mechanism configured to mechanically secure the interface member 300 to the console 301 to prevent the interface member 300 from being accidentally disengaged during a treatment procedure.
The console 301 may also include a user interface 312, which may comprise a display device and/or a touch-screen display. The user may operate the percutaneous heart pump system by interacting with the user interface 312 to select, e.g., desired flow rates and other treatment parameters. The user may also monitor properties of the procedure on the user interface 312.
The interface region 303 can also include one or more pumps, e.g., peristaltic pumps in some embodiments. The peristaltic pumps can be used to pump fluid into or out of the catheter assembly 100A to deliver medical fluids and to remove waste fluids, respectively. Such pumps may employ one or more rollers 306 to control delivery of a fluid within a respective tube (see, e.g., pump tube segments 324a, 324b of
An electrical interconnect 307 can also be provided in the back wall of the aperture 304. The electrical interconnect 307 can be configured to provide power to the motor assembly and/or electrical signals or instructions to control the operation of the motor assembly. The electrical interconnect 307 can also be configured to receive electrical signals indicative of sensor readings for monitoring pressure, flow rates, and/or temperature of one or more components in the catheter assembly 100A. A recessed channel 309 can extend from the bottom of the aperture 304 along the side to the lower edge of the console 301. The recessed channel 309 can be shaped and sized to receive one or more of the conduits 302 (e.g., electrical and/or fluid conduits) extending between the interface member 300 and the motor assembly. In one embodiment, all of the conduits 302 can be received within the channel 309 providing a flush side surface when the interface member 300 is disposed in the interface aperture 304.
In addition, it can be important to ensure that the interface member 300 is controllably secured within the console 301 such that it is engaged and disengaged only when the user desires to engage or disengage the interface member 300 from the console 301. For example, as explained in more detail herein relative to
Removable Interface Member
The interface member 300 can further include first and second pump tube segments 324a, 324b positioned along the occlusion beds 322a, 322b formed in the interface member 300. When the interface member 300 is inserted into the console 301, the pump rollers 306 can engage with the interface member 300 and compress the tube segment(s) 324a, 324b against the occlusion bed(s) 322a, 322b, respectively. As the pump motor(s) in the console 301 rotate the rollers 306, fluid flows into uncompressed portions of the tube segment(s) 324a, 324b and continues flowing throughout the catheter assembly 100A. For example, by compressing the tube segments 324a, 324b, the fluid may be pumped into or out of the catheter assembly 100A by way of the conduits 302 extending from the interface member 300 to the motor assembly and distally beyond the motor assembly.
Because the tolerances for the peristaltic pump can be rather tight, the body of the interface member 300 (e.g., the outer body 333 and/or an inner body, such as inner body 339 illustrated in
For example, the gap between the rollers 306 and the occlusion beds 322a, 322b can be less than about two wall thicknesses of the tube segments 324a, 324b in some arrangements, such that the tubes 324a, 324b can be effectively occluded. Due to the precise tolerances of the interface member 300, the pump can be engaged by simply inserting the interface member 300 into the console 301. There is no need to separately activate the pump in some embodiments. The dimensions of the interface member 300 may be selected such that the occlusion bed(s) 322a, 322b automatically engages the respective pump rollers 306 upon insertion of the interface member 300 into the console 301.
The above configuration provides several advantages. As one of skill in the art will appreciate from the description herein, the interface member 300 and interface region 303 provide an easy-to-use, quick connection of the tubing segments to one or more respective rollers 306. Moreover, the components can be manufactured easily and cost-effectively because only certain components require tight tolerances and the interface of member 300 to region 303 is essentially self-aligning. The interface also eliminates any need to engage the pump through a second mechanism or operator step, streamlining operation of the heart pump and simplifying the engagement of the catheter assembly 100A to the console 301. Also, in implementations where the console 301 is mounted on an IV pole with rollers, or another type of lightweight cart, for example, the simplified engagement mechanisms disclosed herein can be advantageous because there is only a minimal applied force against the pole, which prevents the pole from rolling or tipping when the pump is engaged.
The pump tube segments 324a, 324b can be mounted on the interface body 300 near or in the respective occlusion beds 322a, 322b. As illustrated, the first and second pump tube segments 324a, 324b can be configured to engage with the pump rollers 306 in the console 301, as explained above. The first and second pump tube segments 324a, 324b can have an arcuate shape (which may be pre-formed in various arrangements) that generally conforms to the curved shape of each respective occlusion bed 322a, 322b. The pump rollers 306 within the console 301 can thereby be positioned within the occlusion beds 322a, 322b to compress the tube segments 324a, 324b against the wall of the occlusion beds 322a, 322b. In addition, a bubble detector tube segment 326 can also be mounted in or on the interface member 300 and can be configured to engage with or be positioned adjacent to the bubble detector 308 illustrated in
The tube segments can be fluidly connected to the remainder of the catheter assembly 100A, including, e.g., one or more lumens of the catheter body, by way of the conduits 302. In operation, therefore, the removable interface member 300 may allow fluid to be pumped into and out of the patient within a controlled system, e.g., such that the fluids within the catheter assembly 100A can be pumped while maintaining a sterile environment for the fluids. Depending on the implementation, the volume of medical solution into the catheter body can be equal to, or can exceed by a minimum amount, the volume of medical solution out of the catheter body to assure that blood does not enter a blood-free portion of the heart pump.
In addition, one or more electrical contacts 328 can be provided in the interface member 300. The electrical contacts 328 can be any suitable electrical interface configured to transmit electrical signals between the console 301 and the catheter assembly 100A (e.g., the motor assembly and/or any suitable sensors). For example, the electrical contacts 328 can be configured to electrically couple to the electrical interconnect 307 disposed in the console 301. Electrical control signals and/or power may be transmitted between the console 301 and the catheter assembly 100A by way of the electrical connection between the electrical contacts 328 and the electrical interconnect 307. Advantageously, the electrical connection between the electrical contacts 328 and the electrical interconnect 307 may be formed or completed when the interface member 300 is inserted into the interface region 303 of the console 301. For example, in some embodiments, the electrical connection between the electrical contacts 328 and the electrical interconnect 307 may be formed substantially simultaneously with the fluid connection (e.g., the engagement of the pump) when the interface member 300 is inserted into the interface region 303. In some aspects, for example, the electrical connection can be formed by inserting electrical pins from the electrical contacts 328 into corresponding holes of the electrical interconnect 307 of the console 301, or vice versa.
Further, as shown in
One will appreciate from the description herein that the configuration of the pump rollers, occlusion bed, and tubing can be modified depending on the application in accordance with the present inventions. For example, the configuration may be modified to provide easier access for service and repair. In various embodiments, the pump rollers may be disposed external to the console. In various embodiments, the pump rollers and occlusion bed may be both disposed within the cassette. In various embodiments, the console includes a mechanism to actuate the pump rollers in the cassette. In various embodiments, the rollers may be fixed. In various embodiments, the rollers may be configured to rotate, translate, or both. The rollers and/or the occlusion bed may be positioned on a base that is configured to move. In some embodiments, the console-cassette interface can include a positive pressure interface to pump fluid (e.g., saline) into the patient's vasculature and a negative pressure interface to pump fluid (e.g., waste fluid) out of the patient's vasculature.
Locking Mechanism
As discussed above, the interface member 300 advantageously can be fully engaged with the console 301 by simply inserting it into a correspondingly shaped aperture 304 in the housing of the console 301. When interface member 300 is brought into adjacency with a back wall of the interface region 303 of the console, e.g., when the interface member 300 is inserted into the aperture 304, the fluid handling and electrical connections are made, and the system 350 is operational. A locking mechanism in the interface member 300 can be provided for additional security, which can be particularly useful for patient transport and other more dynamic settings. For example, it is desirable to ensure that the catheter assembly 100A is secured to the console 301 during the entire procedure to ensure that the procedure is not disrupted due to accidental disengagement of the interface member 300 from the console 301.
In one embodiment, the locking mechanism can be disposed between the console 301 and the interface member 300 and can be configured to be engaged by a minimal movement of an actuator. For example, the manual interface 320 can be provided to cause engagement of a locking device by a small rotational turn of the manual interface 320 relative to the console 301.
The inner body 339 of the interface member 300A, 300B can further include a protrusion 330 that includes the tab 332 at a distal portion of the protrusion 330. When the interface member 300A is in the unlocked configuration, the protrusion 330 can be disposed in or near the recess 337 of the cam 335 in the manual interface 320. The cam 335 may therefore not contact or apply a force against the protrusion 330 when the interface member 300A is in the unlocked configuration, as shown in
However, once the interface member 300 is inserted into the console 301, the interface member 300 can be locked into place by rotating the manual interface 320 relative to the inner body 339 and the console 301, e.g., rotated in the A-direction illustrated in
In some embodiments, the protrusion 330 can be a cantilevered protrusion from the inner body 339. As mentioned above, it can be important to maintain tight tolerances between the occlusion beds 322a, 322b, which is also formed in the interface member, and the pump rollers 306 when the interface member 300 engages with the console 301. Because the occlusion beds 322a, 322b may be formed in the same body as the cantilevered protrusions 330, conventional manufacturing processes, such as molding processes, can be used to manufacture the interface member 300 (e.g., the outer body 333 and/or the inner body 339) according to precise dimensions. Thus, the protrusion(s) 330, tab(s) 332 and the occlusion bed(s) 322a, 322b can be made within tight dimensional tolerances, and the tab(s) 332 and/or protrusion(s) 330 can be positioned relative to the occlusion bed(s) 322a, 322b with very high precision such that when the interface member 300 is engaged with the console 301, the tube segments 324a, 324b are optimally occluded. Moreover, because the interface member 300 can be locked by rotating the manual interface 320 on the interface member 300, only minimal forces are applied to the console 301. This enhances the advantages of minimizing disruption of a mobile cart or IV pole to which the system may be coupled.
Disengagement Mechanism
It can also be important to provide a disengagement mechanism configured to decouple the interface member 300 from the console 301. With reference to
As shown in
Electrical Interconnections, Components, and Cables
For example, the electrical component 340 of the interface member 300 can include the one or more electrical contacts 328 configured to mate with the corresponding electrical interconnect 307 in the console 301. The electrical contacts 328 and/or the electrical interconnect 307 can be, for example, nine-pin electrical interconnects, although any suitable interconnect can be used. The motor assembly that drives the operative device (e.g., impeller) of the catheter pump can be electrically connected to the interface member 300 by way of one or more electrical cables, e.g., the conduits 302. In turn, the console 301 can be coupled to a power source, which can drive the catheter pump motor assembly by way of the interface member's contacts 328 and the electrical conduits 302 connecting the interface member 300 to the motor assembly. The electrical component 340 can also include communications interconnects configured to relay electrical signals between the console 301 and the catheter pump motor assembly or other portions of the catheter assembly 100A. For example, a controller within the console 301 (or interface member) can send instructions to the catheter pump motor assembly via the electrical component 340 between the console 301 and the interface member 300. In some embodiments, the electrical component 340 can include interconnects for sensors (such as pressure or temperature sensors) within the catheter assembly 100A, including sensors at the operative device. The sensors may be used to measure a characteristic of the fluid in one or more of the tubes (e.g., saline pressure). The sensors may be used to measure an operational parameter of the system (e.g., ventricular or aortic pressure). The sensors may be provided as part of an adjunctive therapy.
The electrical component 340 within the interface member 300 can be used to electrically couple the cable (and the motor assembly, sensors, etc.) with the corresponding interconnects 307 in the console 301. For example, one or more internal connectors 346 and 348 on the second side of the electrical component 340 may provide electrical communication between the contacts 328 (configured to couple to the interconnects 307 of the console 301) and the catheter assembly 100. For example, electrical cables (e.g., the conduits 302) can couple to a first internal connector 346 and a second internal connector 348. The internal connectors 346, 348 may electrically communicate with the contacts 328 on the first side of the electrical component 340, which in turn communicate with the interconnects 307 of the console 301.
In various embodiments, the electrical component 340 is fluidly sealed to prevent the internal electronics from getting wet. This may be advantageous in wet and/or sterile environments. This may also advantageously protect the electronics in the event one of the fluid tubes leaks or bursts, which is a potential risk in high pressure applications.
In addition, the electrical component 340 (e.g., PCB) can include various electrical or electronic components mounted thereon. As shown in
Priming and Infusate System and Apparatus
One embodiment of an infusate system 1300 is illustrated in
The system 1300 of
As illustrated in the embodiment of
In some aspects, a waste fluid line 1304 can fluidly connect the catheter body 120 with a waste reservoir 1310. A pressure sensor 1309c, which may be disposed on or coupled to the interface member 1313, can measure the pressure of the fluid within the waste fluid line 1304. A pumping mechanism 1306b, such as a roller pump, for example, can be coupled to the interface member 1313 and can pump the waste fluid through the waste fluid line 1304 to the waste reservoir 1310.
The priming operation can proceed by introducing fluid into the sealed priming apparatus 1400 to expel air from the impeller assembly 116A and the elongate body 174A. Fluid can be introduced into the priming apparatus 1400 in a variety of ways. For example, fluid can be introduced distally through the elongate body 174A into the priming apparatus 1400. In other embodiments, an inlet, such as a luer, can optionally be formed on a side of the primer housing 1401 to allow for introduction of fluid into the priming apparatus 1400.
A gas permeable membrane can be disposed on a distal end 1404 of the primer housing 1401. The gas permeable membrane can permit air to escape from the primer housing 1401 during priming.
The priming apparatus 1400 also can advantageously be configured to collapse an expandable portion of the catheter assembly 100A. The primer housing 1401 can include a funnel 1415 where the inner diameter of the housing decreases from distal to proximal. The funnel may be gently curved such that relative proximal movement of the impeller housing causes the impeller housing to be collapsed by the funnel 1415. During or after the impeller housing has been fully collapsed, the distal end 170A of the elongate body 174A can be moved distally relative to the collapsed housing. After the impeller housing is fully collapsed and retracted into the elongate body 174A of the sheath assembly, the catheter assembly 100A can be removed from the priming housing 1400 before a percutaneous heart procedure is performed, e.g., before the pump is activated to pump blood. The embodiments disclosed herein may be implemented such that the total time for infusing the system is minimized or reduced. For example, in some implementations, the time to fully infuse the system can be about six minutes or less. In other implementations, the infusate time can be less than 5 minutes, less than 4 minutes, or less than 3 minutes. In yet other implementations, the total time to infuse the system can be about 45 seconds or less. It should be appreciated that lower infusate times can be advantageous for use with cardiovascular patients.
Preparing a Percutaneous Heart Pump for Insertion into the Vasculature
As discussed herein and in the incorporated patent applications, in various embodiments the heart pump is inserted in a less invasive manner, e.g., using techniques that can be employed in a catheter lab.
Prior to insertion of the catheter assembly 100A of the heart pump, various techniques can be used to prepare the system for insertion. For example, as discussed in connection with
In one technique, the biocompatible liquid is pushed under positive pressure from the proximal end through the catheter assembly 100A until all gas is removed from voids therein. One technique for confirming that all gas has been removed is to observe the back-pressure or the current draw of the pump. As discussed above, the priming apparatus 1400 can be configured to permit gas to escape while preventing saline or other biocompatible liquid from escaping. As such, the back-pressure or current draw to maintain a pre-selected flow will change dramatically once all gas has been evacuated.
In another technique, the priming apparatus 1400 can include a source of negative pressure for drawing a biocompatible liquid into the proximal end of the catheter assembly 100A. Applying a negative pressure to the priming apparatus 1400 can have the advantage of permitting the catheter assembly 100A to be primed separate from the pumps that are used during operation of the heart pump. As a result, the priming can be done in parallel with other medical procedures on the patient by an operator that is not directly working on the patient.
In another approach, a positive pressure pump separate from the pump that operates the heart pump can be used to prime under positive pressure applied to the proximal end. Various priming methods may also be expedited by providing a separate inlet for faster filling of the enclosed volume of the priming apparatus 1400.
Collapsing an Expandable Housing of a Fully Primed Catheter Assembly
A further aspect of certain methods of preparing the catheter assembly 100A for insertion into a patient can involve collapsing the impeller housing 116A. The collapsed state of the impeller housing 116A reduces the size, e.g., the crossing profile, of the distal end of the system. This enables a patient to have right, left or right and left side support through a small vessel that is close to the surface of the skin, e.g., using catheter lab-type procedures. As discussed above, in one technique the priming apparatus 1400 has a funnel configuration that has a large diameter at a distal end and a smaller diameter at a proximal end. The funnel gently transitions from the large to the small diameter. The small diameter is close to the collapsed size of the impeller housing 116A and the large diameter is close to or larger than the expanded size of the impeller housing 116A. In one method, after the catheter assembly 100A has been primed, the impeller housing 116A can be collapsed by providing relative movement between the priming apparatus 1400 and the impeller housing 116A. For example, the priming housing 1400 can be held in a fixed position, e.g., by hand, and the catheter assembly 100A can be withdrawn until at least a portion of the impeller assembly 116A is disposed in the small diameter segment of the priming apparatus 1400. Thereafter, the elongate body 174A of the sheath assembly can be advanced over the collapsed impeller assembly 116A.
In another technique, the catheter assembly 100A is held still and the priming apparatus 1400 is slid distally over the impeller assembly 116A to cause the impeller assembly 116A to collapse. Thereafter, relative movement between the elongate body 174A and the impeller assembly 116A can position the distal end 170A of the elongate body 174A over the impeller assembly 116A after the catheter assembly 100A has been fully primed.
Although the inventions herein have been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present inventions. It is therefore to be understood that numerous modifications can be made to the illustrative embodiments and that other arrangements can be devised without departing from the spirit and scope of the present inventions as defined by the appended claims. Thus, it is intended that the present application cover the modifications and variations of these embodiments and their equivalents.
Any and all applications for which a foreign or domestic priority claim is identified, including U.S. Application No. 61/780,656, filed Mar. 13, 2013, entitled Fluid Handling System, (hereinafter “the '656 priority application”) are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1902418 | Pilgrim | Mar 1933 | A |
2356659 | Aguiar | Oct 1942 | A |
2649052 | Weyer | Aug 1953 | A |
2664050 | Abresch | Dec 1953 | A |
2684035 | Kemp | Jul 1954 | A |
2789511 | Warren | Apr 1957 | A |
2896926 | Chapman | Jul 1959 | A |
2935068 | Donaldson | May 1960 | A |
3080824 | Boyd et al. | Mar 1963 | A |
3455540 | Marcmann | Jul 1969 | A |
3510229 | Smith | May 1970 | A |
3812812 | Hurwitz | May 1974 | A |
3860968 | Shapiro | Jan 1975 | A |
3904901 | Renard et al. | Sep 1975 | A |
3995617 | Watkins et al. | Dec 1976 | A |
4115040 | Knorr | Sep 1978 | A |
4129129 | Amrine | Dec 1978 | A |
4135253 | Reich et al. | Jan 1979 | A |
4143425 | Runge | Mar 1979 | A |
4149535 | Volder | Apr 1979 | A |
4304524 | Coxon et al. | Dec 1981 | A |
D264134 | Xanthopoulos | Apr 1982 | S |
4382199 | Isaacson | May 1983 | A |
4392836 | Sugawara | Jul 1983 | A |
4458366 | MacGregor | Jul 1984 | A |
4537561 | Xanthopoulos | Aug 1985 | A |
4540402 | Aigner | Sep 1985 | A |
4560375 | Schulte et al. | Dec 1985 | A |
4589822 | Clausen et al. | May 1986 | A |
4625712 | Wampler | Dec 1986 | A |
4655745 | Corbett | Apr 1987 | A |
4673334 | Allington et al. | Jun 1987 | A |
4686982 | Nash | Aug 1987 | A |
4704121 | Moise | Nov 1987 | A |
4728319 | Masch | Mar 1988 | A |
4753221 | Kensey et al. | Jun 1988 | A |
4769006 | Papantonakos | Sep 1988 | A |
4817586 | Wampler | Apr 1989 | A |
4846152 | Wampler et al. | Jul 1989 | A |
4895557 | Moise et al. | Jan 1990 | A |
4900227 | Trouplin | Feb 1990 | A |
4902272 | Milder et al. | Feb 1990 | A |
4906229 | Wampler | Mar 1990 | A |
4908012 | Moise et al. | Mar 1990 | A |
4919647 | Nash | Apr 1990 | A |
4944722 | Carriker et al. | Jul 1990 | A |
4955856 | Phillips | Sep 1990 | A |
4957504 | Chardack | Sep 1990 | A |
4964864 | Summers et al. | Oct 1990 | A |
4969865 | Hwang et al. | Nov 1990 | A |
4976270 | Parl et al. | Dec 1990 | A |
4985014 | Orejola | Jan 1991 | A |
4994017 | Yozu | Feb 1991 | A |
4995857 | Arnold | Feb 1991 | A |
5000177 | Hoffman et al. | Mar 1991 | A |
5021048 | Buckholtz | Jun 1991 | A |
5044902 | Malbec | Sep 1991 | A |
5045072 | Castillo et al. | Sep 1991 | A |
5049134 | Golding et al. | Sep 1991 | A |
5059174 | Vaillancourt | Oct 1991 | A |
5061256 | Wampler | Oct 1991 | A |
5074756 | Davis | Dec 1991 | A |
5089016 | Millner et al. | Feb 1992 | A |
5092844 | Schwartz et al. | Mar 1992 | A |
5098256 | Smith | Mar 1992 | A |
5106368 | Uldall et al. | Apr 1992 | A |
5112200 | Isaacson et al. | May 1992 | A |
5112292 | Hwang et al. | May 1992 | A |
5112349 | Summers et al. | May 1992 | A |
5129883 | Black | Jul 1992 | A |
5142155 | Mauze et al. | Aug 1992 | A |
5147186 | Buckholtz | Sep 1992 | A |
5163910 | Schwartz et al. | Nov 1992 | A |
5171212 | Buck et al. | Dec 1992 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5201679 | Velte et al. | Apr 1993 | A |
5211546 | Isaacson et al. | May 1993 | A |
5221270 | Parker | Jun 1993 | A |
5234416 | Macaulay et al. | Aug 1993 | A |
5282787 | Wortrich | Feb 1994 | A |
5290227 | Pasque | Mar 1994 | A |
5300112 | Barr | Apr 1994 | A |
5312341 | Turi | May 1994 | A |
5344443 | Palma et al. | Sep 1994 | A |
5346458 | Affeld | Sep 1994 | A |
5360317 | Clausen et al. | Nov 1994 | A |
5364342 | Beuchat et al. | Nov 1994 | A |
5376114 | Jarvik | Dec 1994 | A |
5393197 | Lemont et al. | Feb 1995 | A |
5393207 | Maher et al. | Feb 1995 | A |
5397222 | Moss et al. | Mar 1995 | A |
5405341 | Martin | Apr 1995 | A |
5405383 | Barr | Apr 1995 | A |
5437541 | Vainrub et al. | Aug 1995 | A |
5449342 | Hirose et al. | Sep 1995 | A |
5458459 | Hubbard et al. | Oct 1995 | A |
5490763 | Abrams et al. | Feb 1996 | A |
5505701 | Anaya Fernandez de Lomana | Apr 1996 | A |
5527159 | Bozeman, Jr. et al. | Jun 1996 | A |
5533957 | Aldea | Jul 1996 | A |
5534287 | Lukic | Jul 1996 | A |
5586868 | Lawless et al. | Dec 1996 | A |
5588812 | Taylor et al. | Dec 1996 | A |
5601420 | Warner et al. | Feb 1997 | A |
5613935 | Jarvik | Mar 1997 | A |
5643226 | Cosgrove et al. | Jul 1997 | A |
5678306 | Bozeman, Jr. et al. | Oct 1997 | A |
5692882 | Bozeman et al. | Dec 1997 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5704926 | Sutton | Jan 1998 | A |
5707218 | Maher et al. | Jan 1998 | A |
5722930 | Larson et al. | Mar 1998 | A |
5725513 | Ju et al. | Mar 1998 | A |
5725570 | Heath | Mar 1998 | A |
5730628 | Hawkins | Mar 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5738649 | Macoviak | Apr 1998 | A |
5741234 | Aboul-Hosn | Apr 1998 | A |
5741429 | Donadio, III et al. | Apr 1998 | A |
5746709 | Rom et al. | May 1998 | A |
5749855 | Reitan | May 1998 | A |
5755784 | Jarvik | May 1998 | A |
5776111 | Tesio | Jul 1998 | A |
5776161 | Globerman | Jul 1998 | A |
5776190 | Jarvik | Jul 1998 | A |
5779721 | Nash | Jul 1998 | A |
5807311 | Palestrant | Sep 1998 | A |
5814011 | Corace | Sep 1998 | A |
5824070 | Jarvik | Oct 1998 | A |
5851174 | Jarvik et al. | Dec 1998 | A |
5868702 | Stevens | Feb 1999 | A |
5868703 | Bertolero | Feb 1999 | A |
5888241 | Jarvik | Mar 1999 | A |
5888242 | Antaki et al. | Mar 1999 | A |
5904668 | Hyman et al. | May 1999 | A |
5911685 | Siess et al. | Jun 1999 | A |
5921913 | Siess | Jul 1999 | A |
5927956 | Lim et al. | Jul 1999 | A |
5941813 | Sievers et al. | Aug 1999 | A |
5951263 | Taylor et al. | Sep 1999 | A |
5957941 | Ream | Sep 1999 | A |
5964694 | Siess et al. | Oct 1999 | A |
5993420 | Hyman et al. | Nov 1999 | A |
6007478 | Siess et al. | Dec 1999 | A |
6007479 | Rottenberg et al. | Dec 1999 | A |
6015272 | Antaki et al. | Jan 2000 | A |
6015434 | Yamane | Jan 2000 | A |
6018208 | Maher et al. | Jan 2000 | A |
6027863 | Donadio, III et al. | Feb 2000 | A |
6056719 | Mickley | May 2000 | A |
6058593 | Siess | May 2000 | A |
6059760 | Sandmore et al. | May 2000 | A |
6068610 | Ellis et al. | May 2000 | A |
6071093 | Hart | Jun 2000 | A |
6083260 | Aboul-Hosn | Jul 2000 | A |
6086527 | Talpade | Jul 2000 | A |
6086570 | Aboul-Hosn et al. | Jul 2000 | A |
6106494 | Saravia et al. | Aug 2000 | A |
6109895 | Ray et al. | Aug 2000 | A |
6113536 | Aboul-Hosn et al. | Sep 2000 | A |
6123659 | Le Blanc et al. | Sep 2000 | A |
6123725 | Aboul-Hosn | Sep 2000 | A |
6132363 | Freed et al. | Oct 2000 | A |
6135943 | Yu et al. | Oct 2000 | A |
6136025 | Barbut et al. | Oct 2000 | A |
6139487 | Siess | Oct 2000 | A |
6152704 | Aboul-Hosn et al. | Nov 2000 | A |
6162194 | Shipp | Dec 2000 | A |
6176822 | Nix et al. | Jan 2001 | B1 |
6176848 | Rau et al. | Jan 2001 | B1 |
6186665 | Maher et al. | Feb 2001 | B1 |
6190304 | Downey et al. | Feb 2001 | B1 |
6200260 | Bolling | Mar 2001 | B1 |
6203528 | Deckert et al. | Mar 2001 | B1 |
6210133 | Aboul-Hosn et al. | Apr 2001 | B1 |
6210397 | Aboul-Hosn et al. | Apr 2001 | B1 |
6214846 | Elliott | Apr 2001 | B1 |
6217541 | Yu | Apr 2001 | B1 |
6227797 | Watterson et al. | May 2001 | B1 |
6228063 | Aboul-Hosn | May 2001 | B1 |
6234960 | Aboul-Hosn et al. | May 2001 | B1 |
6234995 | Peacock, III | May 2001 | B1 |
6245007 | Bedingham et al. | Jun 2001 | B1 |
6245026 | Campbell et al. | Jun 2001 | B1 |
6247892 | Kazatchkov et al. | Jun 2001 | B1 |
6248091 | Voelker | Jun 2001 | B1 |
6254359 | Aber | Jul 2001 | B1 |
6254564 | Wilk et al. | Jul 2001 | B1 |
6287319 | Aboul-Hosn et al. | Sep 2001 | B1 |
6287336 | Globerman et al. | Sep 2001 | B1 |
6295877 | Aboul-Hosn et al. | Oct 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6305962 | Maher et al. | Oct 2001 | B1 |
6387037 | Bolling et al. | May 2002 | B1 |
6395026 | Aboul-Hosn et al. | May 2002 | B1 |
6413222 | Pantages et al. | Jul 2002 | B1 |
6422990 | Prem | Jul 2002 | B1 |
6425007 | Messinger | Jul 2002 | B1 |
6428464 | Bolling | Aug 2002 | B1 |
6447441 | Yu et al. | Sep 2002 | B1 |
6468298 | Pelton | Oct 2002 | B1 |
6494694 | Lawless et al. | Dec 2002 | B2 |
6503224 | Forman et al. | Jan 2003 | B1 |
6508777 | Macoviak et al. | Jan 2003 | B1 |
6508787 | Erbel et al. | Jan 2003 | B2 |
6517315 | Belady | Feb 2003 | B2 |
6517528 | Pantages et al. | Feb 2003 | B1 |
6532964 | Aboul-Hosn et al. | Mar 2003 | B2 |
6533716 | Schmitz-Rode et al. | Mar 2003 | B1 |
6544216 | Sammler et al. | Apr 2003 | B1 |
6547519 | de Blanc et al. | Apr 2003 | B2 |
6565598 | Lootz | May 2003 | B1 |
6572349 | Sorensen et al. | Jun 2003 | B2 |
6609883 | Woodard et al. | Aug 2003 | B2 |
6610004 | Viole et al. | Aug 2003 | B2 |
6613008 | Aboul-Hosn et al. | Sep 2003 | B2 |
6616323 | McGill | Sep 2003 | B2 |
6623420 | Reich et al. | Sep 2003 | B2 |
6623475 | Siess | Sep 2003 | B1 |
6641558 | Aboul-Hosn et al. | Nov 2003 | B1 |
6645241 | Strecker | Nov 2003 | B1 |
6660014 | Demarais et al. | Dec 2003 | B2 |
6673105 | Chen | Jan 2004 | B1 |
6692318 | McBride | Feb 2004 | B2 |
6709418 | Aboul-Hosn et al. | Mar 2004 | B1 |
6716189 | Jarvik et al. | Apr 2004 | B1 |
6749598 | Keren et al. | Jun 2004 | B1 |
6776578 | Belady | Aug 2004 | B2 |
6776794 | Hong et al. | Aug 2004 | B1 |
6783328 | Lucke et al. | Aug 2004 | B2 |
6790171 | Grundeman et al. | Sep 2004 | B1 |
6794784 | Takahashi et al. | Sep 2004 | B2 |
6794789 | Siess et al. | Sep 2004 | B2 |
6814713 | Aboul-Hosn et al. | Nov 2004 | B2 |
6817836 | Nose et al. | Nov 2004 | B2 |
6835049 | Ray | Dec 2004 | B2 |
6860713 | Hoover | Mar 2005 | B2 |
6866625 | Avre et al. | Mar 2005 | B1 |
6866805 | Hong et al. | Mar 2005 | B2 |
6887215 | McWeeney | May 2005 | B2 |
6889082 | Bolling et al. | May 2005 | B2 |
6901289 | Dahl et al. | May 2005 | B2 |
6926662 | Aboul-Hosn et al. | Aug 2005 | B1 |
6935344 | Aboul-Hosn et al. | Aug 2005 | B1 |
6942611 | Siess | Sep 2005 | B2 |
6949066 | Bearnson et al. | Sep 2005 | B2 |
6962488 | Davis et al. | Nov 2005 | B2 |
6966748 | Woodard et al. | Nov 2005 | B2 |
6972956 | Franz et al. | Dec 2005 | B2 |
6974436 | Aboul-Hosn et al. | Dec 2005 | B1 |
6981942 | Khaw et al. | Jan 2006 | B2 |
6984392 | Bechert et al. | Jan 2006 | B2 |
7010954 | Siess et al. | Mar 2006 | B2 |
7011620 | Siess | Mar 2006 | B1 |
7014417 | Salomon | Mar 2006 | B2 |
7018182 | O'Mahony et al. | Mar 2006 | B2 |
7022100 | Aboul-Hosn et al. | Apr 2006 | B1 |
7027875 | Siess et al. | Apr 2006 | B2 |
7037069 | Arnold et al. | May 2006 | B2 |
7070555 | Siess | Jul 2006 | B2 |
7122019 | Kesten et al. | Oct 2006 | B1 |
7125376 | Viole et al. | Oct 2006 | B2 |
7144365 | Bolling et al. | Dec 2006 | B2 |
7150711 | Nusser et al. | Dec 2006 | B2 |
7160243 | Medvedev | Jan 2007 | B2 |
7172551 | Leasure | Feb 2007 | B2 |
7175588 | Morello | Feb 2007 | B2 |
7214038 | Saxer et al. | May 2007 | B2 |
7229258 | Wood et al. | Jun 2007 | B2 |
7238010 | Hershberger et al. | Jul 2007 | B2 |
7241257 | Ainsworth et al. | Jul 2007 | B1 |
7262531 | Li et al. | Aug 2007 | B2 |
7264606 | Jarvik et al. | Sep 2007 | B2 |
7267667 | Houde et al. | Sep 2007 | B2 |
7284956 | Nose et al. | Oct 2007 | B2 |
7288111 | Holloway et al. | Oct 2007 | B1 |
7329236 | Keren et al. | Feb 2008 | B2 |
7331921 | Viole et al. | Feb 2008 | B2 |
7335192 | Keren et al. | Feb 2008 | B2 |
7341570 | Keren et al. | Mar 2008 | B2 |
7381179 | Aboul-Hosn et al. | Jun 2008 | B2 |
7393181 | McBride et al. | Jul 2008 | B2 |
7393189 | Davis et al. | Jul 2008 | B2 |
7469716 | Parrino et al. | Dec 2008 | B2 |
7478999 | Limoges | Jan 2009 | B2 |
7491163 | Viole et al. | Feb 2009 | B2 |
7534258 | Gomez | May 2009 | B2 |
7547200 | O'Mahony et al. | Jun 2009 | B2 |
7605298 | Bechert et al. | Oct 2009 | B2 |
7619560 | Penna | Nov 2009 | B2 |
7632079 | Hershberger et al. | Dec 2009 | B2 |
7645225 | Medvedev et al. | Jan 2010 | B2 |
7657324 | Westlund et al. | Feb 2010 | B2 |
7682673 | Houston et al. | Mar 2010 | B2 |
7731675 | Aboul-Hosn et al. | Jun 2010 | B2 |
7736296 | Siess et al. | Jun 2010 | B2 |
7744566 | Pirovano et al. | Jun 2010 | B2 |
7758521 | Morris et al. | Jul 2010 | B2 |
7766892 | Keren et al. | Aug 2010 | B2 |
7780628 | Keren et al. | Aug 2010 | B1 |
7785246 | Aboul-Hosn et al. | Aug 2010 | B2 |
7811279 | John | Oct 2010 | B2 |
7819833 | Ainsworth et al. | Oct 2010 | B2 |
7820205 | Takakusagi et al. | Oct 2010 | B2 |
7828710 | Shifflette | Nov 2010 | B2 |
7841976 | McBride et al. | Nov 2010 | B2 |
7878967 | Khanal | Feb 2011 | B1 |
7927068 | McBride et al. | Apr 2011 | B2 |
7934912 | Voltenburg, Jr. et al. | May 2011 | B2 |
7935102 | Breznock et al. | May 2011 | B2 |
7942804 | Khaw | May 2011 | B2 |
7942844 | Moberg et al. | May 2011 | B2 |
7955365 | Doty | Jun 2011 | B2 |
7993259 | Kang et al. | Aug 2011 | B2 |
7998054 | Bolling | Aug 2011 | B2 |
8012079 | Delgado | Sep 2011 | B2 |
8025647 | Siess et al. | Sep 2011 | B2 |
8052399 | Stemple et al. | Nov 2011 | B2 |
8062008 | Voltenburg, Jr. et al. | Nov 2011 | B2 |
8079948 | Shifflette | Dec 2011 | B2 |
8083503 | Voltenburg et al. | Dec 2011 | B2 |
8110267 | Houston et al. | Feb 2012 | B2 |
8114008 | Hidaka et al. | Feb 2012 | B2 |
8123669 | Siess et al. | Feb 2012 | B2 |
8142400 | Rotem et al. | Mar 2012 | B2 |
8177703 | Smith et al. | May 2012 | B2 |
8206350 | Mann et al. | Jun 2012 | B2 |
8209015 | Glenn | Jun 2012 | B2 |
8235943 | Breznock et al. | Aug 2012 | B2 |
8236044 | Robaina | Aug 2012 | B2 |
8255050 | Mohl | Aug 2012 | B2 |
8257054 | Voltenburg et al. | Sep 2012 | B2 |
8257312 | Duffy | Sep 2012 | B2 |
8262619 | Chebator et al. | Sep 2012 | B2 |
8277470 | Demarais et al. | Oct 2012 | B2 |
8317715 | Belleville et al. | Nov 2012 | B2 |
8329913 | Murata et al. | Dec 2012 | B2 |
8348991 | Weber et al. | Jan 2013 | B2 |
8364278 | Pianca et al. | Jan 2013 | B2 |
8371832 | Rotem et al. | Feb 2013 | B2 |
8376707 | McBride et al. | Feb 2013 | B2 |
8382818 | Davis et al. | Feb 2013 | B2 |
8388565 | Shifflette | Mar 2013 | B2 |
8388582 | Eubanks et al. | Mar 2013 | B2 |
8409128 | Ferrari | Apr 2013 | B2 |
8439859 | Pfeffer et al. | May 2013 | B2 |
8449443 | Rodefeld | May 2013 | B2 |
8485961 | Campbell et al. | Jul 2013 | B2 |
8489190 | Pfeffer et al. | Jul 2013 | B2 |
8491285 | Haser et al. | Jul 2013 | B2 |
8535211 | Campbell et al. | Sep 2013 | B2 |
8540615 | Aboul-Hosn et al. | Sep 2013 | B2 |
8545379 | Marseille et al. | Oct 2013 | B2 |
8545380 | Farnan et al. | Oct 2013 | B2 |
8579858 | Reitan | Nov 2013 | B2 |
8585572 | Mehmanesh | Nov 2013 | B2 |
8591393 | Walters et al. | Nov 2013 | B2 |
8597170 | Walters et al. | Dec 2013 | B2 |
8617239 | Reitan | Dec 2013 | B2 |
8684904 | Campbell et al. | Apr 2014 | B2 |
8721516 | Scheckel | May 2014 | B2 |
8721517 | Zeng et al. | May 2014 | B2 |
8727959 | Reitan et al. | May 2014 | B2 |
8734331 | Evans et al. | May 2014 | B2 |
8795576 | Tao et al. | Aug 2014 | B2 |
8801590 | Mohl | Aug 2014 | B2 |
8814776 | Hastie et al. | Aug 2014 | B2 |
8814933 | Siess | Aug 2014 | B2 |
8849398 | Evans | Sep 2014 | B2 |
8944748 | Liebing | Feb 2015 | B2 |
8992406 | Corbett | Mar 2015 | B2 |
8998792 | Scheckel | Apr 2015 | B2 |
9028216 | Schumacher et al. | May 2015 | B2 |
20020094287 | Davis | Jul 2002 | A1 |
20030018380 | Craig et al. | Jan 2003 | A1 |
20030205233 | Aboul-Hosn et al. | Nov 2003 | A1 |
20030208097 | Aboul-Hosn et al. | Nov 2003 | A1 |
20030225366 | Morgan et al. | Dec 2003 | A1 |
20030231959 | Snider | Dec 2003 | A1 |
20040116862 | Ray | Jun 2004 | A1 |
20040253129 | Sorensen et al. | Dec 2004 | A1 |
20050013698 | Davis | Jan 2005 | A1 |
20050049696 | Siess et al. | Mar 2005 | A1 |
20050085683 | Bolling et al. | Apr 2005 | A1 |
20050113631 | Bolling et al. | May 2005 | A1 |
20050165269 | Aboul-Hosn et al. | Jul 2005 | A9 |
20050277912 | John | Dec 2005 | A1 |
20060018943 | Bechert et al. | Jan 2006 | A1 |
20060058869 | Olson et al. | Mar 2006 | A1 |
20060063965 | Aboul-Hosn et al. | Mar 2006 | A1 |
20060089521 | Chang | Apr 2006 | A1 |
20060155158 | Aboul-Hosn | Jul 2006 | A1 |
20060167404 | Pirovano et al. | Jul 2006 | A1 |
20060264695 | Viole et al. | Nov 2006 | A1 |
20060270894 | Viole et al. | Nov 2006 | A1 |
20070100314 | Keren et al. | May 2007 | A1 |
20070212240 | Voyeux et al. | Sep 2007 | A1 |
20070217932 | Voyeux et al. | Sep 2007 | A1 |
20070248477 | Nazarifar et al. | Oct 2007 | A1 |
20080015506 | Davis | Jan 2008 | A1 |
20080103442 | Kesten et al. | May 2008 | A1 |
20080119943 | Armstrong et al. | May 2008 | A1 |
20080132748 | Shifflete | Jun 2008 | A1 |
20080167679 | Papp | Jul 2008 | A1 |
20080200878 | Davis et al. | Aug 2008 | A1 |
20080275290 | Viole et al. | Nov 2008 | A1 |
20090053085 | Thompson et al. | Feb 2009 | A1 |
20090112312 | LaRose et al. | Apr 2009 | A1 |
20090118567 | Siess | May 2009 | A1 |
20090182188 | Marseille et al. | Jul 2009 | A1 |
20100030186 | Stivland | Feb 2010 | A1 |
20100041939 | Siess | Feb 2010 | A1 |
20100094089 | Litscher et al. | Apr 2010 | A1 |
20100127871 | Pontin | May 2010 | A1 |
20100137802 | Yodfat et al. | Jun 2010 | A1 |
20100174239 | Yodfat et al. | Jul 2010 | A1 |
20100210895 | Aboul-Hosn et al. | Aug 2010 | A1 |
20100268017 | Siess | Oct 2010 | A1 |
20100274330 | Burwell et al. | Oct 2010 | A1 |
20110015610 | Plahey et al. | Jan 2011 | A1 |
20110071338 | McBride et al. | Mar 2011 | A1 |
20110076439 | Zeilon | Mar 2011 | A1 |
20110218516 | Grigorov | Sep 2011 | A1 |
20110237863 | Ricci et al. | Sep 2011 | A1 |
20110300010 | Jarnagin et al. | Dec 2011 | A1 |
20120004495 | Bolling | Jan 2012 | A1 |
20120142994 | Toellner | Jun 2012 | A1 |
20120178986 | Campbell et al. | Jul 2012 | A1 |
20120220854 | Messerly et al. | Aug 2012 | A1 |
20120224970 | Schumacher et al. | Sep 2012 | A1 |
20120226097 | Smith et al. | Sep 2012 | A1 |
20120245404 | Smith et al. | Sep 2012 | A1 |
20120265002 | Roehn et al. | Oct 2012 | A1 |
20130041202 | Toellner | Feb 2013 | A1 |
20130053622 | Corbett | Feb 2013 | A1 |
20130053623 | Evans et al. | Feb 2013 | A1 |
20130053693 | Breznock et al. | Feb 2013 | A1 |
20130066140 | McBride et al. | Mar 2013 | A1 |
20130085318 | Toellner | Apr 2013 | A1 |
20130129503 | McBride et al. | May 2013 | A1 |
20130138205 | Kushwaha et al. | May 2013 | A1 |
20130237744 | Pfeffer et al. | Sep 2013 | A1 |
20130303969 | Keenan et al. | Nov 2013 | A1 |
20130303970 | Keenan et al. | Nov 2013 | A1 |
20130345492 | Pfeffer et al. | Dec 2013 | A1 |
20140005467 | Farnan et al. | Jan 2014 | A1 |
20140010686 | Tanner et al. | Jan 2014 | A1 |
20140012065 | Fitzgerald et al. | Jan 2014 | A1 |
20140275726 | Zeng et al. | Sep 2014 | A1 |
20150051435 | Siess et al. | Feb 2015 | A1 |
20150080743 | Siess | Mar 2015 | A1 |
20150087890 | Spanier et al. | Mar 2015 | A1 |
20150151032 | Voskoboynikov | Jun 2015 | A1 |
Number | Date | Country |
---|---|---|
2701810 | Apr 2009 | CA |
101820933 | Sep 2010 | CN |
0 533 432 | Sep 1992 | EP |
1 207 934 | May 2002 | EP |
1 591 079 | Nov 2005 | EP |
2 298 374 | Mar 2011 | EP |
2 263 732 | Dec 2012 | EP |
2267800 | Apr 1974 | FR |
2 239 675 | Jul 1991 | GB |
S48-23295 | Mar 1973 | JP |
06-114101 | Apr 1994 | JP |
10-099447 | Apr 1998 | JP |
2011-000620 | Sep 2005 | JP |
500877 | Sep 2002 | TW |
WO 8905164 | Jun 1989 | WO |
WO 9715228 | May 1997 | WO |
WO 9737697 | Oct 1997 | WO |
WO 0012148 | Mar 2000 | WO |
WO 0019097 | Apr 2000 | WO |
WO 0069489 | Nov 2000 | WO |
WO 0124867 | Apr 2001 | WO |
WO 02070039 | Sep 2002 | WO |
WO 03103745 | Dec 2003 | WO |
WO 2005089674 | Sep 2005 | WO |
WO 2005123158 | Dec 2005 | WO |
WO 2009073037 | Jun 2009 | WO |
WO 2009076460 | Jun 2009 | WO |
WO 2010127871 | Nov 2010 | WO |
WO 2010133567 | Nov 2010 | WO |
WO 2010149393 | Dec 2010 | WO |
WO 2011035926 | Mar 2011 | WO |
WO 2011035929 | Mar 2011 | WO |
WO 2011039091 | Apr 2011 | WO |
WO 2011076439 | Jun 2011 | WO |
WO 2011089022 | Jul 2011 | WO |
WO 2012007140 | Jan 2012 | WO |
WO 2012007141 | Jan 2012 | WO |
WO 2013160407 | Oct 2013 | WO |
WO 2014019274 | Feb 2014 | WO |
Entry |
---|
ABIOMED, “Impella 5.0 with the Impella Console, Circulatory Support System, Instructions for Use & Clinical Reference Manual,” Jun. 2010, in 122 pages. |
ABIOMED—Recovering Hearts. Saving Lives., Impella 2.5 System, Instructions for Use, Jul. 2007, in 86 sheets. |
Barras et al., “Nitinol—Its Use in Vascular Surgery and Other Applications,” Eur. J. Vasc. Endovasc. Surg., 2000, pp. 564-569; vol. 19. |
Biscarini et al., “Enhanced Nitinol Properties for Biomedical Applications,” Recent Patents on Biomedical Engineering, 2008, pp. 180-196, vol. 1(3). |
Cardiovascular Diseases (CVDs) Fact Sheet No. 317; World Health Organization [Online], Sep. 2011. http://www.who.int/mediacentre/factsheets/fs317/en/index.html, accessed on Aug. 29, 2012. |
Duerig et a., “An Overview of Nitinol Medical Applications,” Materials Science Engineering, 1999, pp. 149-160; vol. A273. |
European Search Report received in European Patent Application No. 05799883.3, dated May 10, 2011, in 4 pages. |
Extended European Search Report received in European Patent Application No. 07753903.9, dated Oct. 8, 2012, in 7 pages. |
Federal and Drug Administration 510(k) Summary for Predicate Device IMPELLA 2.5 (K112892), prepared Sep. 5, 2012. |
Grech, “Percutaneous Coronary Intervention. I: History and Development,” BMJ., May 17, 2003, pp. 1080-1082, vol. 326. |
Hsu et al., “Review of Recent Patents on Foldable Ventricular Assist Devices,” Recent Patents on Biomedical Engineering, 2012, pp. 208-222, vol. 5. |
Ide et al., “Evaluation of the Pulsatility of a New Pulsatile Left Ventricular Assist Device—the Integrated Cardioassist Catheter-in Dogs,” J. of Thorac and Cardiovasc Sur, Feb. 1994, pp. 569-0575, vol. 107(2). |
Ide et al., “Hemodynamic Evaluation of a New Left Ventricular Assist Device: An Integrated Cardioassist Catheter as a Pulsatile Left Ventricle—Femoral Artery Bypass,” Blackwell Scientific Publications, Inc., 1992, pp. 286-290, vol. 16(3). |
International Preliminary Examination Report received in International Patent Application No. PCT/US2003/04853, mailed on Jul. 26, 2004, in 5 pages. |
International Preliminary Examination Report received in International Patent Application No. PCT/US2003/04401, dated May 18, 2004, in 4 pages. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority received in International Patent Application No. PCT/US2005/033416, mailed on Mar. 20, 2007, in 7 pages. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority received in International Patent Application No. PCT/US2007/007313, mailed on Sep. 23, 2008, in 6 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2005/033416, mailed on Dec. 11, 2006, in 8 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2007/007313, mailed on Mar. 4, 2008, in 6 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2012/020382, mailed on Jul. 31, 2012, in 11 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2012/020369, mailed on Jul. 30, 2012, in 10 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2012/020553, mailed on Aug. 17, 2012, in 8 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2012/020383, mailed on Aug. 17, 2012; in 9 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2013/040798, mailed Aug. 21, 2013, in 16 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2013/040799, mailed Aug. 21, 2013, in 19 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2013/040809, mailed Sep. 2, 2013, in 25 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2013/048332, mailed Oct. 16, 2013, in 17 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2013/048343, mailed Oct. 11, 2013, in 15 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2014/020878, mailed May 7, 2014, in 13 pages. |
International Search Report received in International Patent Application No. PCT/US2003/004401, mailed on Nov. 10, 2003, in 9 pages. |
International Search Report received in International Patent Application No. PCT/US2003/004853, mailed on Jul. 3, 2003, in 3 pages. |
International Search Report Written Opinion received in International Patent Application No. PCT/US2010/040847, mailed on Dec. 14, 2010, in 17 pages. |
Krishnamani et al., “Emerging Ventricular Assist Devices for Long-Term Cardiac Support,” National Review, Cardiology, Feb. 2010, pp. 71-76, vol. 7. |
Mihaylov et al., “Development of a New Introduction Technique for the Pulsatile Catheter Pump,” Artificial Organs, 1997, pp. 425-427; vol. 21(5). |
Mihaylov et al., “Evaluation of the Optimal Driving Mode During Left Ventricular Assist with Pulsatile Catheter Pump in Calves,” Artificial Organs, 1999, pp. 1117-1122; vol. 23(12). |
Morgan, “Medical Shape Memory Alloy Applications—The Market and its Products,” Materials Science and Engineering, 2004, pp. 16-23, vol. A 378. |
Morsink et al., “Numerical Modelling of Blood Flow Behaviour in the Valved Catheter of the PUCA-Pump, a LVAD,” The International Journal of Artificial Organs, 1997, pp. 277-284; vol. 20(5). |
Nishimura et al, “The Enabler Cannula Pump: A Novel Circulatory Support System,” The International Journal of Artificial Organs, 1999, pp. 317-323; vol. 22(5). |
Petrini et al., “Biomedical Applications of Shape Memory Alloys,” Journal of Metallurgy, 2011, pp. 1-15. |
Raess et al., “Impella 2.5,” J. Cardiovasc. Transl. Res., 2009, pp. 168-172, vol. 2(2). |
Rakhorst et al., “In Vitro Evaluation of the Influence of Pulsatile Intraventricular Pumping on Ventricular Pressure Patterns,” Artificial Organs, 1994, pp. 494-499, vol. 18(7). |
Reitan et al., “Hemodynamic Effects of a New Percutaneous Circulatory Support Device in a Left Ventricular Failure Model,” ASAIO Journal, 2003, pp. 731-736, vol. 49. |
Reitan et al., “Hydrodynamic Properties of a New Percutaneous Intra-Aortic Axial Flow Pump,” ASAIO Journal 2000, pp. 323-328. |
Schmitz-Rode et al., “An Expandable Percutaneous Catheter Pump for Left Ventricular Support,” Journal of the American College of Cardiology, 2005, pp. 1856-1861, vol. 45(11). |
Shabari et al., “Improved Hemodynamics with a Novel Miniaturized Intra-Aortic Axial Flow Pump in a Porcine Model of Acute Left Ventricular Dysfunction,” ASAIO Journal, 2013, pp. 240-245; vol. 59. |
Sharony et al, “Cardiopulmonary Support and Physiology—The Intra-Aortic Cannula Pump: A Novel Assist Device for the Acutely Failing Heart,” The Journal of Thoracic and Cardiovascular Surgery, Nov. 1992, pp. 924-929, vol. 118(5). |
Sharony et al., “Right Heart Support During Off-Pump Coronary Artery Surgery—A Multi-Center Study,” The Heart Surgery Forum, 2002, pp. 13-16, vol. 5(1). |
Smith et al., “First-In-Man Study of the Reitan Catheter Pump for Circulatory Support in Patients Undergoing High-Risk Percutaneous Coronary Intervention,” Catheterization and Cardiovascular Interventions, 2009, pp. 859-865, vol. 73(7). |
Sokolowski et al., “Medical Applications of Shape Memory Polymers,” Biomed. Mater. 2007, pp. S23-S27, vol. 2. |
“Statistical Analysis and Clinical Experience with the Recover® Pump Systems”, Impella CardioSystems GmbH, 2 sheets. |
Stoeckel et al., “Self-Expanding Nitinol Stents—Material and Design Considerations,” European Radiology, 2003, in 13 sheets. |
Stolinski et al., “The heart-pump interaction: effects of a microaxial blood pump,” International Journal of Artificial Organs, 2002, pp. 1082-1088, vol. 25, Issue 11. |
Supplemental European Search Report received from the European Patent Office in EP Application No. EP 05799883 dated Mar. 19, 2010, 3 pages. |
Takagaki et al., “A Novel Miniature Ventricular Assist Device for Hemodynamic Support,” ASAIO Journal, 2001, pp. 412-416; vol. 47. |
Throckmorton et al., “Flexible Impeller Blades in an Axial Flow Pump for Intravascular Cavopulmonary Assistance of the Fontan Physiology,” Cardiovascular Engineering and Technology, Dec. 2010, pp. 244-255, vol. 1(4). |
Verkerke et al., “Numerical Simulation of the PUCA Pump, A Left Ventricular Assist Device,” Abstracts of the XIXth ESAO Congress, The International Journal of Artificial Organs, 1992, p. 543, vol. 15(9). |
Verkerke et al., “Numerical Simulation of the Pulsating Catheter Pump: A Left Ventricular Assist Device,” Artificial Organs, 1999, pp. 924-931, vol. 23(10). |
Verkerke et al., “The PUCA Pump: A Left Ventricular Assist Device,” Artificial Organs, 1993, pp. 365-368, vol. 17(5). |
Wampler et al., “The Sternotomy Hemopump, A Second Generation Intraarterial Ventricular Assist Device,” ASAIO Journal, 1993, pp. M218-M223, vol. 39. |
Weber et al., “Principles of Impella Cardiac Support,” Supplemental to Cardiac Interventions Today, Aug./Sep. 2009. |
Written Opinion received in International Patent Application No. PCT/US2003/04853, dated Feb. 25, 2004, 5 pages. |
Kunst et al., “Integrated unit for programmable control of the 21F Hemopump and registration of physiological signals,” Medical & Biological Engineering & Computing, Nov. 1994, pp. 694-696. |
Throckmorton et al., “Uniquely shaped cardiovascular stents enhance the pressure generation of intravascular blood pumps,” The Journal of Thoracic and Cardiovascular Surgery, Sep. 2012, pp. 704-709, vol. 133, No. 3. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2014/020790, mailed Aug. 6, 2014, in 11 pages. |
Aboul-Hosn et al., “The Hemopump: Clinical Results and Future Applications”, Assisted Circulation 4, 1995, in 14 pages. |
Compendium of Technical and Scientific Information for the HEMOPUMP Temporary Cardiac Assist System, Johnson & Johnson Interventional Systems, 1988, in 15 pages. |
Dekker et al., “Efficacy of a New lntraaortic Propeller Pump vs the lntraaortic Balloon Pump, An Animal Study”, Chest, Jun. 2003, vol. 123, No. 6, pp. 2089-2095. |
Impella CP®—Instructions for Use & Clinical Reference Manual (United States only), Abiomed, Inc., Jul. 2014, 148 pages, www.abiomed.com. |
Impella LD® with the Impella® Controller—Circulatory Support System—Instructions for Use & Clinical Reference Manual (United States only), Abiomed, Inc., Sep. 2010, 132 pages, www.abiomed.com. |
International Preliminary Report on Patentability and Written Opinion received in International Patent Application No. PCT/US2014/020878, mailed Sep. 15, 2015, in 8 pages. |
International Search Reort and Written Opinion received in International Patent Application No. PCT/US2015/026013, mailed Jul. 8, 2015, in 12 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2015/026014, mailed Jul. 15, 2015, in 13 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2015/026025, mailed Jul. 20, 2015, in 12 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2015/025959, mailed Aug. 28, 2015, in 16 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2015/025960, mailed Sep. 3, 2015, in 15 pages. |
International Search Report and Written Opinion received in International Patent Application No. PCT/US2015/045370, mailed Nov. 18, 2015, in 12 pages. |
JOMED Reitan Catheter Pump RCP, Percutaneous Circulatory Support, in 10 pages. |
JOMED Reitan Catheter Pump RCP, Feb. 18, 2003, in 4 pages. |
Minimally Invasive Cardiac Assist JOMED Catheter PumpTM, in 6 pages. |
Reitan, Evaluation of a New Percutaneous Cardiac Assist Device, Department of Cardiology, Faculty of Medicine, Lund University, Sweden, 2002, in 172 pages. |
Rothman, “The Reitan Catheter Pump: A New Versatile Approach for Hemodynamic Support”, London Chest Hospital Barts & The London NHS Trust, Oct. 22-27, 2006 (TCT 2006: Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium, Final Program), in 48 pages. |
Sieβ et al., “Hydraulic refinement of an intraarterial microaxial blood pump”, The International Journal of Artificial Organs, 1995, vol. 18, No. 5, pp. 273-285. |
Sieβ, “Systemanalyse und Entwicklung intravasaler Rotationspumpen zur Herzunterstützung”, Helmholtz-Institut fur Blomedixinische Technik an der RWTH Aachen, Jun. 24, 1998, in 105 pages. |
Siess et al., “Basic design criteria for rotary blood pumps,” H. Masuda, Rotary Blood Pumps, Springer, Japan, 2000, pp. 69-83. |
Siess et al., “Concept, realization, and first in vitro testing of an intraarterial microaxial blood pump,” Artificial Organs, 1995, pp. 644-652, vol. 19, No. 7, Blackwell Science, Inc., Boston, International Society for Artificial Organs. |
Siess et al., “From a lab type to a product: A retrospective view on Impella's assist technology,” Artificial Organs, 2001, pp. 414-421, vol. 25, No. 5, Blackwell Science, Inc., International Society for Artificial Organs. |
Siess et al., “System analysis and development of intravascular rotation pumps for cardiac assist,” Dissertation, Shaker Verlag, Aachen, 1999, 39 pages. |
Number | Date | Country | |
---|---|---|---|
20140275725 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
61780656 | Mar 2013 | US |